Louisbourg Investments Inc. Sells 149 Shares of Cencora, Inc. (NYSE:COR)

Louisbourg Investments Inc. lessened its holdings in Cencora, Inc. (NYSE:COR) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 488 shares of the company’s stock after selling 149 shares during the period. Louisbourg Investments Inc.’s holdings in Cencora were worth $110,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Concord Wealth Partners bought a new stake in Cencora in the third quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co bought a new stake in Cencora in the fourth quarter worth $33,000. Ashton Thomas Securities LLC bought a new stake in Cencora in the third quarter worth $41,000. Finally, Modus Advisors LLC bought a new stake in Cencora in the fourth quarter worth $54,000. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on COR. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Barclays boosted their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Up 0.2 %

Shares of COR opened at $246.86 on Wednesday. The firm has a market capitalization of $47.71 billion, a P/E ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The firm has a fifty day moving average price of $238.86 and a 200-day moving average price of $237.03.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities research analysts expect that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock valued at $17,790,912 over the last three months. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.